Osimertinib in EGFR T790M Advanced NSCLC: Analysis of Uncommon/Complex EGFR Mutations in a Real-World Study (ASTRIS)

被引：4
作者：
Cheema, P. [1 ]
Passaro, A. [2 ]
Martin, C. [3 ]
Tiseo, M. [4 ]
Park, K. [5 ]
Chang, G. [6 ,7 ,8 ]
Hu, Y. [9 ]
Cho, B. C. [10 ]
Miranda, M. [11 ]
Fernandes, A. [12 ]
Freitas, H. [13 ]
机构：
[1] Univ Toronto, Sunnybrook Odette Canc Ctr, William Osler Hlth Syst, Toronto, ON, Canada
[2] European Inst Oncol Irccs, Ieo, Div Thorac Oncol, Milan, Italy
[3] Inst Alexander Fleming, Dept Oncol, Buenos Aires, DF, Argentina
[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
[6] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Fac Med, Sch Med, Taichung, Taiwan
[8] Natl Yang Ming Univ, Taichung, Taiwan
[9] Hubei Canc Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[12] Astrazeneca Us, Gaithersburg, MD USA
[13] AC Camargo Canc Ctr, Clin Res Unit, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; EGFR; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-59
引用
收藏
页码：S854 / S854
页数：1
相关论文
共 50 条
  • [31] Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M
    Masuhiro, Kentaro
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Takata, So
    Nasu, Shingo
    Takada, Hiromune
    Morita, Satomu
    Tanaka, Ayako
    Morishita, Naoko
    Okamoto, Norio
    Hirashima, Tomonori
    ANTICANCER RESEARCH, 2018, 38 (06) : 3567 - 3571
  • [32] Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study
    Qin, Yi
    Long, Yaling
    Tang, Yuan
    Tian, Yuke
    Li, Juan
    Duan, Ping
    Luo, Jieyan
    Yu, Min
    Li, Yanying
    Zhou, Xiaojuan
    Wang, Ke
    Gong, Youling
    Peng, Feng
    Zhu, Jiang
    Liu, Yongmei
    Zhou, Lin
    Lu, You
    Huang, Meijuan
    CANCER SCIENCE, 2023, 114 (06) : 2552 - 2559
  • [33] Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
    Passaro, Antonio
    Guerini-Rocco, Elena
    Pochesci, Alessia
    Vacirca, Davide
    Spitaleri, Gianluca
    Catania, Chiara Matilde
    Rappa, Alessandra
    Barberis, Massimo
    de Marinis, Filippo
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 406 - 415
  • [34] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
    A. Cortellini
    A. Leonetti
    A. Catino
    P. Pizzutillo
    B. Ricciuti
    A. De Giglio
    R. Chiari
    P. Bordi
    D. Santini
    R. Giusti
    M. De Tursi
    D. Brocco
    F. Zoratto
    F. Rastelli
    F. Citarella
    M. Russano
    M. Filetti
    P. Marchetti
    R. Berardi
    M. Torniai
    D. Cortinovis
    E. Sala
    C. Maggioni
    A. Follador
    M. Macerelli
    O. Nigro
    A. Tuzi
    D. Iacono
    M. R. Migliorino
    G. Banna
    G. Porzio
    K. Cannita
    M. G. Ferrara
    E. Bria
    D. Galetta
    C. Ficorella
    M. Tiseo
    Clinical and Translational Oncology, 2020, 22 : 844 - 851
  • [35] Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
    Qing Zhou
    He-Long Zhang
    Li-Yan Jiang
    Yuan-Kai Shi
    Yuan Chen
    Jin-Ming Yu
    Cai-Cun Zhou
    Yong He
    Yan-Ping Hu
    Zong-An Liang
    Yue-Yin Pan
    Wen-Lei Zhuo
    Yong Song
    Gang Wu
    Gong-Yan Chen
    You Lu
    Cui-Ying Zhang
    Yi-Ping Zhang
    Ying Cheng
    Shun Lu
    Chang-Li Wang
    Jian-Ying Zhou
    Yun-Peng Liu
    Jian-Xing He
    Jie Wang
    Yi-Long Wu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 10771 - 10780
  • [36] Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
    Zhou, Qing
    Zhang, He-Long
    Jiang, Li-Yan
    Shi, Yuan-Kai
    Chen, Yuan
    Yu, Jin-Ming
    Zhou, Cai-Cun
    He, Yong
    Hu, Yan-Ping
    Liang, Zong-An
    Pan, Yue-Yin
    Zhuo, Wen-Lei
    Song, Yong
    Wu, Gang
    Chen, Gong-Yan
    Lu, You
    Zhang, Cui-Ying
    Zhang, Yi-Ping
    Cheng, Ying
    Lu, Shun
    Wang, Chang-Li
    Zhou, Jian-Ying
    Liu, Yun-Peng
    He, Jian-Xing
    Wang, Jie
    Wu, Yi-Long
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10771 - 10780
  • [37] Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
    Xinyue Wang
    Zhaona Li
    Liuchun Wang
    Yan Liang
    Chun Huang
    Peng Chen
    Dingzhi Huang
    Xia Song
    Cuimin Ding
    Changli Wang
    Richeng Jiang
    BMC Medicine, 23 (1)
  • [38] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    Peng, Da
    Shan, Dongfeng
    Dai, Chengcheng
    Li, Jie
    Wang, Zifan
    Huang, Ziyi
    Peng, Rui
    Zhao, Peng
    Ma, Xuezhen
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
  • [39] Association between EGFR T790M Mutation Copy Numbers in Cell -Free Plasma DNA and Response to Osimertinib in Advanced NSCLC
    Buder, Anna
    Hochmair, Maximilian
    Holzer, Sophia
    Mohn-Staudner, Andrea
    Errhalt, Peter
    Sundalo, Tatjana
    Schenk, Peter
    Setinek, Ulrike
    Burghuber, Otto
    Pirker, Robert
    Filipits, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1205 - S1206
  • [40] Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan
    Seto, Takashi
    Nogami, Naoyuki
    Yamamoto, Nobuyuki
    Atagi, Shinji
    Tashiro, Naoki
    Yoshimura, Yoko
    Yabuki, Yutaka
    Saka, Hideo
    ONCOLOGY AND THERAPY, 2018, 6 (02) : 203 - 215
12345